Literature DB >> 29566395

Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy.

Chung Yee Chung1,2,3, Yee Yan Chan1,2,3, Kenneth K W Li1,2,3.   

Abstract

AIMS: To identify the angiographic and tomographic prognostic factors of chronic central serous chorioretinopathy (CSC) treated with half-dose photodynamic therapy (PDT).
METHODS: This is a consecutive series of 61 eyes with chronic CSC treated with half-dose PDT from January 1, 2009 to October 31, 2016.
RESULTS: The mean logMAR best-corrected visual acuity (BCVA) improved from 0.47 to 0.31 at 3 months (p < 0.001). From multivariate regression, the final BCVA was significantly associated with the baseline BCVA (p = 0.003), a diffuse hyperfluorescence pattern on indocyanine green angiography (ICGA) (p = 0.024), posttreatment shallow irregular pigment epithelium detachment (PED) (p = 0.022), and disruption of the ellipsoid zone (p = 0.007). A diffuse hyperfluorescence pattern on ICGA was associated with a 77.4 times risk of subretinal fluid persistence after treatment (p = 0.009).
CONCLUSION: A poor baseline BCVA, diffuse hyperfluorescence ICGA pattern, shallow irregular PED, and disruption of the ellipsoid zone indicate poor prognosis.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Angiography; Central serous chorioretinopathy; Optical coherence tomography; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 29566395     DOI: 10.1159/000484100

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  6 in total

1.  Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.

Authors:  Mengyang Li; Jinfeng Qu; Zhiqiao Liang; Jiyang Tang; Jie Hu; Yuou Yao; Enzhong Jin; Xiaoxin Li; Mingwei Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-13       Impact factor: 3.117

2.  Outer Nuclear Layer as the Main Predictor to Anatomic Response to Half Dose Photodynamic Therapy in Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Ana Rita Viana; Joana Pires; Carla Ferreira; Lara Queirós; Manuel Falcão
Journal:  J Ophthalmol       Date:  2019-10-13       Impact factor: 1.909

Review 3.  The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy.

Authors:  Stefano Da Pozzo; Pierluigi Iacono; Alessandro Arrigo; Maurizio Battaglia Parodi
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-29

Review 4.  Management of chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

5.  Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach.

Authors:  Elon H C van Dijk; Thomas J van Rijssen; Yousif Subhi; Camiel J F Boon
Journal:  Ophthalmol Ther       Date:  2020-04-11

6.  532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Gil Calvão-Santos; Marina João; Nuno Gomes; Manuel Falcão
Journal:  Clin Ophthalmol       Date:  2020-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.